Babita yadav

Dr. Babita yadav


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 February 2022 in Complementary Therapies in Medicine
Verified
Journal Article
Open access
HSHarbans Singh
Harbans Singh
SSSumit Srivastava
Sumit Srivastava
BYBabita yadav
Babita yadav
ARAmit K. Rai
Amit K. Rai
SJSophia Jameela
Sophia Jameela
SCSarika Chaturvedi
Sarika Chaturvedi
To determine the therapeutic efficacy and safety of AYUSH-64 as an add-on to standard care in mild to moderate COVID-19. This open-label randomized controlled parallel-group trial was conducted at a designated COVID care centre in India in 80 patients diagnosed with mild to moderate COVID-19 and randomized into two groups. Participants in the AYUSH-64 add-on group (AG) received AYUSH-64 two tablets (500 mg each) three times a day for 30 days along with standard conventional care. The control group (CG) received standard care alone. Proportion of participants who attained clinical recovery on day 7, 15, 23 and 30, proportion of participants with negative RT-PCR assay for COVID-19 at each weekly time point, change in pro-inflammatory markers, metabolic functions, HRCT chest (CO-RADS category) and incidence of Adverse Drug Reaction (ADR)/Adverse Event (AE). Out of 80 participants, 74 (37 in each group) contributed to the final analysis. Significant difference was observed in clinical recovery in the AG (p < 0.001 ) compared to CG. Mean duration for clinical recovery in AG (5.8 ± 2.67 days) was significantly less compared to CG (10.0 ± 4.06 days). Significant improvement in HRCT chest was observed in AG (p = 0.031) unlike in CG (p = 0.210). No ADR/SAE was observed or reported in AG. AYUSH-64 as adjunct to standard care is safe and effective in hastening clinical recovery in mild to moderate COVID-19. The efficacy may be further validated by larger multi-center double-blind trials.

19 February 2021 in medRxiv
Verified
Preprint
Open access
PDF file
AGArun Gupta
Arun Gupta
AMAmit Madan
Amit Madan
BYBabita yadav
Babita yadav
PMPallavi Mundada
Pallavi Mundada
RSRicha Singhal
Richa Singhal
KDK. S. Dhiman
K. S. Dhiman
Background: Coronavirus disease 2019 (Covid-19) occurs after exposure to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). For persons who are at high risk of exposure, the standard of care is personal protection from getting infected. Whether Ayurvedic rasayana drug like Chyawanprash can prevent symptomatic infection in frontline health care workers is unknown. Objective: To evaluate the effect of the combination of Chyawanprash and Standard Preventive Regimen compared to the use of Standard Preventive Regimen alone on the proportion of RT-PCR confirmed COVID-19 infections among frontline healthcare workers (HCWs). Methods: An open-label randomized controlled trial was conducted in the HCWs between 25 to 60 years age currently working in an environment with chance of direct exposure to COVID-19 cases. The interventions to be compared in this trial were Standard Preventive Regimen as per institutional guidelines and based on their roles (Group I) and Ayurvedic Intervention viz., Chyawanprash 12 g twice for 30 days from day of randomization plus Standard Preventive Regimen (Group II). The incidence of RT PCR confirmed COVID-19 cases in both groups, was the primary outcome measure. Evaluation of the safety of the study drug (by any statistically significant change in various biochemical and hematological parameters and occurrence of any adverse drug reactions); incidence of any other infective diseases (bacterial /viral/ fungal / etc.) like upper respiratory tract illness during the study period and any change in the immunoglobulins like IgG, IgM and IgE and inflammatory markers like TNF alpha, IL-6 and IL-10 were the secondary outcome measures. Results: Out of 193 participants who completed the study, no participant in both groups was COVID-19 positive at the end of one month. In post intervention follow-up, 4 subjects in Group I and 2 subjects in Group II were COVID-19 positive. No adverse drug reaction or any serious adverse event was reported during the study. No clinically significant change in the safety parameters was observed before and after the study. Statistically significant rise in Serum IgG level was seen in Group II but other inflammatory and immune markers did not show statistically significant difference. Conclusion: Chyawanprash was well tolerated by all the participants in the intervention group but to prove its adaptogenic effect and efficacy as an add-on to the standard care in preventing the occurrence of COVID-19, clinical trial for longer duration with larger sample size is needed. Trial registration: Clinical Trials Registry of India vide CTRI/2020/05/025275 dated 20/05/2020 Date of IEC approval: 19.5.2020

3 June 2021 in Trials
Verified
Journal Article
Open access
PDF file
BYBabita yadav
Babita yadav
ARAmit Rai
Amit Rai
PMPallavi Mundada
Pallavi Mundada
RSRicha Singhal
Richa Singhal
BRB. C. S. Rao
B. C. S. Rao
Narayanam SrikanthNarayanam Srikanth
Narayanam Srikanth
Objectives: Primary Objective • To assess the efficacy of Ayurveda interventions and Yoga in rehabilitation of COVID-19 cases suffering with long term effects of COVID 19 as compared to WHO Rehabilitation Self-Management after COVID-19- Related Illness. Secondary Objective • To assess the safety of Ayurvedic interventions in cases suffering with long term effects of COVID 19 Trial design: Multi-centric, randomized, controlled, parallel group, open-label, exploratory study. The study duration is 9 months and the intervention period is 90 days from the day of enrolment of the participant. Participants: Patients of either sex between 18 to 60 years, ambulatory, willing to participate, with history (not more than 4 weeks) of positive RT-PCR for COVID-19 or IgM antibodies positivity for SARS CoV-2, but having negative RT-PCR for COVID-19 at the time of screening will be considered eligible for enrolment in the study. Critically ill patients with ARDS (acute respiratory distress syndrome), requiring invasive respiratory support in the intensive care unit, known case of any malignancy, immune-compromised state (e.g. HIV), diabetes mellitus, active pulmonary tuberculosis, past history of any chronic respiratory disease, motor neuron disease, multiple sclerosis, stroke, impaired cognition, atrial fibrillation, acute coronary syndrome, myocardial infarction, severe arrhythmia, concurrent serious hepatic disease or renal disease, pregnant or lactating women, patients on immunosuppressive medications, history of hypersensitivity to the trial drugs or their ingredients, depressive illness (before COVID-19), diagnosed psychotic illnesses, substance dependence or alcoholism will be excluded. The trial will be conducted at two medical colleges in Maharashtra, India. Intervention and comparator: Intervention Arm (Group-I): Ayurveda interventions including Agastya Haritaki six gram and Ashwagandha tablet 500 mg twice daily orally after meals with warm water and two sessions of yoga (morning 30 minutes and evening 15 minutes) daily for 90 days, as per the post-COVID-19 care protocol provided in National Clinical Management Protocol based on Ayurveda and Yoga for management of COVID-19 published by Ministry of AYUSH, Government of India. Comparator Arm (Group-II): WHO Rehabilitation Self-Management after COVID-19 related illness for 90 days. The trial drugs are being procured from a GMP certified pharmaceutical company. Main outcomes: Primary Outcome: Change in respiratory function to be assessed by San Diego shortness of breath Questionnaire, 6-minutes walk test and pulmonary function test. Secondary Outcomes: Change in High-resolution Computed Tomography (HRCT) Chest Change in Fatigue score assessed by Modified Fatigue Impact Scale Change in Anxiety score assessed by Hospital Anxiety and Depression Scale Score Change in Sleep Quality assessed by Pittsburgh Sleep Quality Index Change in the quality of life assessed by COV19-QoL scale Safety of the interventions will be assessed by comparing hematological and biochemical investigations before and after the intervention period and Adverse Event/ Adverse drug reaction Timelines for Outcome assessment: Subjective parameters and clinical assessment will be assessed at baseline, 15th day, 30th day, 60th day and 90th day. Laboratory parameters (CBC, LFT, KFT, HbA1c, Hs-CRP, D-dimer), Pulmonary function test and HRCT Chest will be done at baseline and after completion of study period i.e. 90th day. Randomisation: Statistical package for Social Sciences (SPSS) version 15.0 is used to generate the random number sequences. The participants will be randomized to two study groups in the ratio of 1:1. Blinding (masking): The study is open-label design. However, the outcome assessor will be kept blinded regarding the study group allocation of the participants. Numbers to be randomised (sample size) Sample size: The sample size for the study is calculated assuming improvement in 6-minutes walk test by 40 meter in Group I and a change of 10 meter in Group II with a standard deviation of 50 meter based on the results of the previous studies, with 95% Confidence Level (α = 0.05) and 80% power and expecting a dropout rate of 20%. The number of participants to be enrolled in the study should be approximately 55 in each group. Hence, a total of 110 participants will be enrolled in the trial at each study site. Trial Status: Participants’ recruitment started on 1st May 2021. Anticipated end of recruitment is August 2021. Protocol number: CCRAS-01 Protocol version number: 1.1, 13th January 2021. Trial registration: The trial is prospectively registered with the Clinical Trial Registry of India (CTRI) on 03rd March 2021 [CTRI/2021/03/031686]. Full protocol: The full protocol is attached as an additional file, accessible from the Journal website (Additional file 1). This communication serves as a summary of the key elements of the full protocol.

24 May 2022 in Systematic Reviews
Verified
Journal Article
Open access
PDF file
ARAmit Kumar Rai
Amit Kumar Rai
AAAZEEM AHMAD
AZEEM AHMAD
PMPallavi Mundada
Pallavi Mundada
KVKrishna Kumar V
Krishna Kumar V
BYBabita yadav
Babita yadav
Narayanam SrikanthNarayanam Srikanth
Narayanam Srikanth
Trial registration: Registered with PROSPERO (CRD42021267844) dated 14.07.2021.

1 October 2022 in Journal of Research in Ayurvedic Sciences
Verified
Journal Article
Closed access
BRBcs Rao
Bcs Rao
BYBabita yadav
Babita yadav
MSMm Sharma
Mm Sharma
SJSophia Jameela
Sophia Jameela
RRRakesh Kumar Rana
Rakesh Kumar Rana
KDKartar Singh Dhiman
Kartar Singh Dhiman
BACKGROUND: The exponential rise of cases and associated morbidity and mortality has managed to make COVID-19 a serious threat. Minimising the transmission of disease by prevention and control strategy forms the core-pillar of response. Ayurveda with its holistic approach can potentially promote disease prophylaxis both at the individual as well as community levels. This clinical study was executed in a community set-up to explore the potential of Ayurvedic interventions in COVID-19 prophylaxis. MATERIALS AND METHODS: The study was conducted as an open label community based study in six selected containment zones of Delhi on 9200 individuals with an objective to record the incidence of COVID-19 in these areas. The selected Ayurvedic Interventions (Ashwagandha, Maha Sudarshan Ghan Vati, Samshamani Vati) were distributed in the dose of two tablets of 250 mg each twice daily after food with lukewarm water for a period of one month. Onset of any COVID-19 related clinical symptoms, patient satisfaction in general health parameters and incidence of ADR/AE were taken as outcome measures. RESULTS: 9010 participants were recruited with mean age of 37.9 years. A total of 12 participants (0.17%) were reported positive during the intervention period, among 279 who underwent testing (because of contact tracing or symptoms). Participants who were devoid of any symptoms throughout the trial period were 98.8%. Statistically significant improvement was observed in parameters of general well-being at the end of study period. CONCLUSION: Ayurveda interventions demonstrated potential as a safe prophylactic measure against COVID 19 with comparatively good compliance and minimal adverse effects.

1 December 2024 in Journal of Clinical and Diagnostic Research
Verified
Journal Article
Closed access
BYBabita yadav
Babita yadav
VKVaishali Kuchewar
Vaishali Kuchewar
BGBharti Gupta
Bharti Gupta
Non Alcoholic Fatty Liver Disease (NAFLD) represents a growing global health concern, particularly driven by rising obesity rates, with prevalence ranging from 11.2 to 37.2% in the general population. Ayurveda classifies NAFLD under Yakrit Roga (liver disease) and Medoroga (obesity), with traditional texts attributing its development to lifestyle factors that lead to imbalances in tridosha. Hereby, the authors present a unique case of 59-year-old male that highlights the therapeutic effects of Ayurveda interventions in managing grade II NAFLD, adding valuable insights to the scientific literature by demonstrating effective treatment in the absence of a standard care protocol. The patient presented with symptoms of indigestion and liver enlargement consistent with grade II NAFLD, confirmed through ultrasonography evaluation. Clinical findings included liver steatosis and mild hepatomegaly. The intervention involved Ayurveda-based therapies tailored to the patient’s condition, focusing on balancing Rakta-Kapha Dushti and dietary modifications based on classical Ayurveda guidelines. Following treatment, the patient experienced complete relief from symptoms of indigestion, and follow-up ultrasonography showed significant improvement, as there was no NAFLD. The present case report illustrates the potential of Chitrakadi Vati and Phaltrikadi Kashaya ghan vati as effective management strategies for NAFLD, particularly in the absence of established standard care. The takeaway lesson is that individualised Ayurveda treatment may offer a viable therapeutic approach for NAFLD, highlighting the importance of integrating traditional medicine into the broader clinical context of liver disorders.